Shared on24 Oct 25
Fair value Increased 8.96%

Thermo Fisher Scientific's analyst price target has been increased from $554 to $604. This reflects analysts' optimism following stronger-than-expected quarterly results and continued outperformance in key life science segments.

Shared on09 Oct 25
Fair value Increased 1.35%

Thermo Fisher Scientific’s analyst price target has increased by approximately $8 to $554. Analysts cite continued market leadership and resilient long-term fundamentals as supporting factors for further upside for the company.

Shared on25 Sep 25
Fair value Decreased 1.16%

Analysts have modestly reduced Thermo Fisher Scientific’s price target to $546.76, balancing optimism over long-term growth catalysts and recent strong performance against short-term headwinds in life sciences R&D and slower anticipated near-term recovery. Analyst Commentary Bullish analysts highlight Thermo Fisher's "one-stop-shop" pharma partnership model, viewing it as a driver for long-term multiple expansion and resilience as a preferred partner in biopharma.

Shared on27 Aug 25
Fair value Increased 0.52%

Analysts raised their price target for Thermo Fisher Scientific to $555.84, citing improved sentiment from strong Q2 results, upward FY25 guidance revisions, and optimism around its resilient pharmaceutical partnership model and recovering end-markets, despite ongoing R&D headwinds. Analyst Commentary Bullish analysts highlight Thermo Fisher's resilient "one-stop-shop" pharma partnership model, expecting it to drive multiple expansion and position the company as a long-term biopharma partner of choice.